The boss of Ozempic maker Novo Nordisk lost his job yesterday after its share price plunged amid intensifying competition in the multi-billion pound fat jab market. Lars Fruergaard Jorgensen is being ...

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

A growing number of users say Ozempic is rewiring their taste buds in ways they never saw coming. Many have complained about unexpected side effects like the Ozempic butt, the Ozempic mouth, and the ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

In a press release announcing the move, Novo Nordisk cited market challenges and its declining share price in a press release ...

For those preferring a drug-free approach to weight loss, research shows that certain nutrients and dietary strategies can naturally mimic the effects of semaglutides.

"Unfortunately, since losing the weight, he's also turned into a jerk. He used to be really friendly and funny, but in recent months he's gotten a lot snobbier." ...

From marathon gym sessions and trendy detox teas to the latest GLP-1 injections, people will try just about anything to get ...

COPENHAGEN (Reuters) - Wegovy-maker Novo Nordisk (NYSE: NVO) ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the ...

Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its ...

The CEO of Danish pharmaceutical giant Novo Nordisk, known for its blockbuster weight-loss drug Ozempic, will step down ...

Novo’s shares have plunged since hitting a record-high in June last year as competition, particularly from Eli Lilly, makes inroads into its market share and as its pipeline of new drugs has ...